Literature DB >> 11980928

Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals.

Corinna Hermann1, Kathrin Graf, Annemarie Groh, Eberhard Straube, Thomas Hartung.   

Abstract

The seroprevalence of anti-Chlamydia pneumoniae-specific immunoglobulin G (IgG) antibodies is high in the adult population. Experience is required to perform a microimmunofluorescence test (MIF), the current "gold standard" for serological diagnosis, and the assay still lacks standardization. Partially automated enzyme-linked immunosorbent assays (ELISAs) and enzyme immunoassays (EIAs), which are more standardized and for which the reading of results is less subjective, have been developed. The different commercially available serological tests differ in their sensitivities and specificities, depending primarily on the antigen used. Therefore, we evaluated 11 different tests (10 were species specific, 1 was genus specific) for IgG antibodies using serum samples of 80 apparently healthy volunteers. The interpretation of the results was based on the results of the gold standard, MIF: a sample was judged positive if it was positive by at least three of the four different MIFs. Based on this internal standard, we found that 71% of the samples were positive, while 8% were false positive by some tests. The correlations between the results of the different MIFs ranged from 83 to 99%, and the correlations between the results of the MIFs and the different ELISAs and EIAs ranged from 78 to 98%. Comparison of the IgG titers measured by MIF showed good agreement (r = 0.76 to 0.91). This analysis revealed that some ELISAs and EIAs fail to detect low IgG titers. The specificities of the species-specific tests varied from 95 to 100%, and the sensitivities varied from 58 to 100%. These results indicate that serological assays for the detection of anti-C. pneumoniae-specific IgG vary greatly in their sensitivities and specificities. MIF must still be considered the best method for the detection of IgG in apparently healthy subjects, but the sensitivities and specificities of new ELISAs approximate those of MIFs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980928      PMCID: PMC130946          DOI: 10.1128/JCM.40.5.1603-1609.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  47 in total

1.  Replicate PCR testing and probit analysis for detection and quantitation of Chlamydia pneumoniae in clinical specimens.

Authors:  M Smieja; J B Mahony; C H Goldsmith; S Chong; A Petrich; M Chernesky
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

2.  Comparison of two commercial microimmunofluorescence kits and an enzyme immunoassay kit for detection of serum immunoglobulin G antibodies to Chlamydia pneumoniae.

Authors:  T O Messmer; J Martinez; F Hassouna; E R Zell; W Harris; S Dowell; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

3.  Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS).

Authors:  H R Chandra; N Choudhary; C O'Neill; J Boura; G C Timmis; W W O'Neill
Journal:  Am J Cardiol       Date:  2001-08-01       Impact factor: 2.778

4.  Differential expression of ompA, ompB, pyk, nlpD and Cpn0585 genes between normal and interferon-gamma treated cultures of Chlamydia pneumoniae.

Authors:  S Mathews; C George; C Flegg; D Stenzel; P Timms
Journal:  Microb Pathog       Date:  2001-06       Impact factor: 3.738

5.  Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual.

Authors:  A Vink; M Poppen; A H Schoneveld; P J Roholl; D P de Kleijn; C Borst; G Pasterkamp
Journal:  Circulation       Date:  2001-03-27       Impact factor: 29.690

6.  Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals.

Authors:  A Schumacher; A B Lerkerød; I Seljeflot; L Sommervoll; I Holme; J E Otterstad; H Arnesen
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

7.  Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity.

Authors:  D Sander; K Winbeck; J Klingelhöfer; T Etgen; B Conrad
Journal:  Circulation       Date:  2001-03-13       Impact factor: 29.690

Review 8.  Chlamydia pneumoniae infection of the central nervous system.

Authors:  C Yucesan; S Sriram
Journal:  Curr Opin Neurol       Date:  2001-06       Impact factor: 5.710

9.  Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells.

Authors:  G I Byrne; S P Ouellette; Z Wang; J P Rao; L Lu; W L Beatty; A P Hudson
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

10.  Prevalence of asymptomatic infection with Chlamydia pneumoniae in subjectively healthy adults.

Authors:  N Miyashita; Y Niki; M Nakajima; H Fukano; T Matsushima
Journal:  Chest       Date:  2001-05       Impact factor: 9.410

View more
  11 in total

1.  Impact of serological methodology on assessment of the link between Chlamydia pneumoniae and vascular diseases.

Authors:  Boulos Maraha; Martin den Heijer; Jan Kluytmans; Marcel Peeters
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

2.  Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland.

Authors:  Mika Paldanius; Aini Bloigu; Marianne Alho; Maija Leinonen; Pekka Saikku
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

3.  Detection of Chlamydia pneumoniae-specific antibodies binding to the VD2 and VD3 regions of the major outer membrane protein.

Authors:  Marcus Klein; Arne Kötz; Katussevani Bernardo; Martin Krönke
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

4.  High immunoglobulin A seropositivity for combined Chlamydia pneumoniae, Helicobacter pylori infection, and high-sensitivity C-reactive protein in coronary artery disease patients in India can serve as atherosclerotic marker.

Authors:  Hem Chandra Jha; Jagdish Prasad; Aruna Mittal
Journal:  Heart Vessels       Date:  2008-11-27       Impact factor: 2.037

5.  Comparison of quantitative and semiquantitative enzyme-linked immunosorbent assays for immunoglobulin G against Chlamydophila pneumoniae to a microimmunofluorescence test for use with patients with respiratory tract infections.

Authors:  Corinna Hermann; Katja Gueinzius; Albrecht Oehme; Sonja Von Aulock; Eberhard Straube; Thomas Hartung
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

6.  Characterization of the humoral immune response to Chlamydia outer membrane protein 2 in chlamydial infection.

Authors:  I Portig; J C Goodall; R L Bailey; J S H Gaston
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

7.  Importance of methodology in determination of Chlamydia pneumoniae seropositivity in healthy subjects and in patients with coronary atherosclerosis.

Authors:  V Y Hoymans; J M Bosmans; L Van Renterghem; R Mak; D Ursi; F Wuyts; C J Vrints; M Ieven
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

8.  Detection of parvovirus B19 and Chlamydophila pneumoniae in a patient with atypical sarcoidosis.

Authors:  C Contini; D Segala; R Cultrera; V M Crapanzano Minichello
Journal:  Infection       Date:  2007-09-28       Impact factor: 7.455

9.  High seroprevalence of Mycoplasma pneumoniae IgM in acute Q fever by enzyme-linked immunosorbent assay (ELISA).

Authors:  Chung-Hsu Lai; Lin-Li Chang; Jiun-Nong Lin; Wei-Fang Chen; Li-Li Kuo; Hsi-Hsun Lin; Yen-Hsu Chen
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

10.  Evaluation and optimization of a commercial enzyme linked immunosorbent assay for detection of Chlamydophila pneumoniae IgA antibodies.

Authors:  Olfa Frikha-Gargouri; Radhouane Gdoura; Abir Znazen; Nozha Ben Arab; Jalel Gargouri; Mounir Ben Jemaa; Adnene Hammami
Journal:  BMC Infect Dis       Date:  2008-07-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.